Saturday 17 October 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5.88% and free cash flow fell 7.00%, each against the same quarter a year earlier.
10.31
0.17
−1.62%
Follow DSGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
18.43 | 16.84 | 21.87 | 18.45 | |
Current Ratio |
18.71 | 17.14 | 22.28 | 18.86 | |
Net Debt/EBITDA |
10.34 | 11.87 | 11.31 | 9.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.66 | 0.75 | 0.93 | 0.77 | |
Capex/Depreciation |
0.00 | 0.10 | 0.00 | (0.15) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.21) | (0.27) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.21) | (0.27) | (0.25) | |
Cash per Share |
3.62 | 3.83 | 3.63 | 3.32 | |
Shareholders Equity per Share |
3.51 | 3.71 | 3.55 | 3.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.51 | 3.71 | 3.55 | 3.23 | |
Free Cash Flow |
(11.16) | (12.00) | (16.43) | (15.54) | |
Working Capital |
197.86 | 210.73 | 216.86 | 200.77 | |
Capital Expenditures |
0.00 | (0.03) | — | (0.02) | |
Net Current Asset Value |
196.98 | 210.08 | 214.66 | 198.74 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
1.69 | 2.25 | 2.73 | 2.08 | |
Average Assets |
236.70 | 239.15 | 233.96 | 219.01 | |
Average Common Equity |
226.09 | 227.30 | 222.99 | 207.45 |
Columns are period end dates